The Alzheimer’s agitation developer is strengthening biostatistics, regulatory and AI-enabled data capabilities as its 146-patient study moves toward a fourth-quarter topline analysis
Newsflash:
The August 11 operating report puts clinic growth, NeuroStar utilisation and cost discipline at the centre of …
The Alzheimer’s agitation developer is strengthening biostatistics, regulatory and AI-enabled data capabilities as its 146-patient study moves toward a fourth-quarter topline analysis
The August 11 operating report puts clinic growth, NeuroStar utilisation and cost discipline at the centre of …
The Alzheimer’s agitation developer is strengthening biostatistics, regulatory and AI-enabled data capabilities as its 146-patient study moves toward a fourth-quarter topline analysis
The August 11 operating report puts clinic growth, NeuroStar utilisation and cost discipline at the centre of …
LEADERS
INVESTMENTS
INNOVATION
PARTNERSHIPS
In-Depth Analysis
In-Depth Analysis
Explore our longform features and deep dives into biotech breakthroughs and innovation.
Expert Opinions
Expert Opinions
Read opinions and commentary from leading scientists, investors, and pharma leaders.
Funding & IPOs
Funding & IPOs
Track the latest funding rounds, IPO announcements, and investment trends in biotech/pharma.
Clinical Results & Milestones
Clinical Results & Milestones
Stay informed on pivotal trial results, FDA approvals, and key clinical milestones.
1
2
3
4
5
6
7
8
9
10
1
2
3
4
5
6
7
8
9
10
The Reporter Newsletter
Expert picks and exclusive deals, in your inbox.
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while combination cohorts continue
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while combination cohorts continue
Watch Now
Depot blast in Bangladesh kills nearly 50 people - BBC News
Russia accused of stealing about 600,000 tonnes of Ukraine's grain - BBC News
Devastation of Australia's climate change crisis captured on camera - BBC News
Boris Johnson survives leadership vote but 41% of his MPs have “no confidence” - BBC News
The Alzheimer’s agitation developer is strengthening biostatistics, regulatory and AI-enabled data capabilities as its 146-patient study moves toward a fourth-quarter …
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, and product …
Listen Now
The oncology company reported $1.7 billion in quarterly revenue and lifted full-year guidance as its flagship BTK inhibitor continued expanding globally
The August 11 agreement gives Sentynl a route to license the oral neutrophil elastase inhibitor while Mereo advances regulatory planning in a genetically defined lung disorder
The Alzheimer’s agitation developer is strengthening biostatistics, regulatory and AI-enabled data capabilities as its 146-patient study moves toward a fourth-quarter topline analysis
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while combination cohorts continue
Ready To Explore Industry News?
All articles are free -no payment or registration required.
Already a subscriber?